The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Key findings of the ALEX study: Improved therapeutic options for ALK-positive NSCLC
The key findings of the anaplastic lymphoma kinase-positive non-small cell lung cancer (ALEX) study (NCT02075840) have established alectinib as a key treatment compared with crizotinib. In this talk, Solange Peters, MD, PhD, from the University of Lausanne, Lausanne, Switzerland, discusses the implications with a new treatment and how alectinib proves to be a superior treatment strategy with regards to these implications. This video was recorded at the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland.
